Efficacy and Safety of TAS-116, an Oral Inhibitor of Heat Shock Protein 90, in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumour Refractory to Imatinib, Sunitinib and Regorafenib: A Phase II, Single-Arm Trial

European Journal of Cancer - United Kingdom
doi 10.1016/j.ejca.2019.08.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Phase II Trial of Imatinib in Metastatic or Unresectable Gastrointestinal Stromal Tumors,NEMROCK Experience.

Research in Oncology
2006English

Phase II Trial of Continuous Regorafenib Dosing in Patients With Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib

Oncologist
Cancer ResearchMedicineOncology
2019English

Regorafenib for Advanced Gastrointestinal Stromal Tumors Following Imatinib and Sunitinib Treatment: A Subgroup Analysis Evaluating Japanese Patients in the Phase III GRID Trial

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2015English

Safety and Efficacy of Regorafenib in Patients With Treatment-Refractory Metastatic Colorectal Cancer in Turkey: The Single-Arm, Open-Label REGARD Study

BMJ Open
Medicine
2020English

Imatinib for the Treatment of Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumours: Systematic Review and Economic Evaluation

Health Technology Assessment
MedicineHealth Policy
2005English

Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–resistant Patients: Recommendations and Evidence

Current Oncology
Oncology
2010English

Comparison of Performance of Various Tumour Response Criteria in Assessment of Regorafenib Activity in Advanced Gastrointestinal Stromal Tumours After Failure of Imatinib and Sunitinib

European Journal of Cancer
Cancer ResearchOncology
2014English

A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy